Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1374)
  2. Journal Article (1150)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Book Section (25)
  7. Correspondence (24)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Hematology-Oncology Fellows (2746)
  2. Department of Medicine (2703)
  3. Solid Tumor Oncology Division (2002)
  4. Hematologic Malignancies, Division of (1330)
  5. GSK Faculty (1228)
  6. Department of Pathology and Laboratory Medicine (982)

More Groups

People
  1. Michael Berger (218)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (176)
  5. Sergio Giralt (171)
  6. Maria Carlo (168)

More People

Years
  1. 2025 (206)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (643)
  2. Elsevier Inc. (343)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (239)
  5. Nature Publishing Group (201)
  6. Oxford University Press (157)

More Publishers

Results (2819)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
    Meeting Abstract

    Yao, J. C.; Strosberg, J.; Fazio, N.; Pavel, M. E.; Ruszniewski, P.; Bergsland, E.; Li, D.; Tafuto, S.; Raj, N.; Campana, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab
    Meeting Abstract

    Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • A high degree of engrafting unit-recipient HLA-allele mismatch is not associated with an increased risk of transplant-related mortality (TRM) or inferior progression-free survival (PFS) after double unit cord blood (CB) transplantation (dCBT) in adults with hematologic malignancies
    Meeting Abstract

    Politikos, I.; Devlin, S. M.; Maloy, M.; Mazis, C.; Naputo, K.; Afuye, A. O.; Scaradavou, A.; Avecilla, S. T.; Castro-Malaspina, H. R.; Cho, C.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • CD34+ selected hematopoietic stem cell transplants conditioned with a myeloablative regimen is well tolerated and results in good outcomes in patients with myelofibrosis
    Meeting Abstract

    Lee, J. O.; Flynn, J.; Maloy, M.; Jakubowski, A. A.; Papadopoulos, E. B.; Cho, C.; Ponce, D.; Sauter, C. S.; Perales, M. A.; Devlin, S. M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of MRD negativity in adults ages 18-60 with Philadelphia chromosome-negative acute lymphoblastic leukemia and lymphoblastic lymphoma
    Meeting Abstract

    Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Cazacu, M. I.; Vemuri, S.; Tallman, M. S.; Douer, D.; Park, J. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Folate testing and deficiency in hospitalized cancer patients
    Meeting Abstract

    Epstein-Peterson, Z. D.; Soff, G. A.; Fenelus, M.; Korenstein, D.
    Blood (2018)

    Fulltext@MSK | Save
  • Choosing for whom to recommend allogeneic transplantation for acute myeloid leukemia in CR1: A continued, complicated conversation
    Journal Article

    Menghrajani, K. N.; Tallman, M. S.
    Blood Advances (2018)

    Fulltext@MSK | Save